Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
Regel 1: | Regel 1: | ||
{| border="1" cellspacing="1" cellpadding="1" width="100%" | {| border="1" cellspacing="1" cellpadding="1" width="100%" | ||
|- | |- | ||
- | | '''Naam''' | + | | '''Naam''' |
- | | '''Firma''' | + | | '''Firma''' |
- | | '''Consultatie/advisering''' | + | | |
- | | '''Wetenschappelijk onderzoek''' | + | '''Consultatie/''' |
- | | '''Congres/andere reis''' | + | |
+ | '''advisering''' | ||
+ | |||
+ | | '''Wetenschappelijk onderzoek''' | ||
+ | | | ||
+ | '''Congres/''' | ||
+ | |||
+ | '''andere reis''' | ||
+ | |||
| '''Cursus''' | | '''Cursus''' | ||
|- | |- | ||
- | | Kees Brinkman | + | | Kees Brinkman |
- | | Viiv | + | | Viiv |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| x | | x | ||
|- | |- | ||
| | | | ||
- | | BMS | + | | BMS |
- | | x | + | | x |
| | | | ||
| | | | ||
Regel 23: | Regel 31: | ||
|- | |- | ||
| | | | ||
- | | MSD | + | | MSD |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Gilead | + | | Gilead |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| x | | x | ||
|- | |- | ||
| | | | ||
- | | Roche | + | | Roche |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Abbott | + | | Abbott |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Jansen-Tibotec | + | | Jansen-Tibotec |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| x | | x | ||
|- | |- | ||
Regel 64: | Regel 72: | ||
| | | | ||
|- | |- | ||
- | | Mariska Tuut | + | | Mariska Tuut |
- | | Geen | + | | Geen |
| | | | ||
| | | | ||
Regel 78: | Regel 86: | ||
| | | | ||
|- | |- | ||
- | | Suzanne Geerlings | + | | Suzanne Geerlings |
- | | MSD | + | | MSD |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | GSK | + | | GSK |
- | | x | + | | x |
| | | | ||
| | | | ||
Regel 93: | Regel 101: | ||
|- | |- | ||
| | | | ||
- | | BMS | + | | BMS |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Gilead | + | | Gilead |
| | | | ||
| | | | ||
- | | x | + | | x |
| x | | x | ||
|- | |- | ||
| | | | ||
- | | Abbott | + | | Abbott |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Jansen Cilag (Tibotec) | + | | Jansen Cilag (Tibotec) |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Pfizer | + | | Pfizer |
| | | | ||
| | | | ||
Regel 134: | Regel 142: | ||
| | | | ||
|- | |- | ||
- | | <span style="background-color: #ffff00">Jet Gisolf</span> | + | | <span style="background-color: #ffff00">Jet Gisolf</span> |
| | | | ||
| | | | ||
Regel 148: | Regel 156: | ||
| | | | ||
|- | |- | ||
- | | Gerrit Schreij | + | | Gerrit Schreij |
- | | Viiv Healthcare | + | | Viiv Healthcare |
- | | x | + | | x |
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Gilead | + | | Gilead |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Tibotec | + | | Tibotec |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | Roche | + | | Roche |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | MSD | + | | MSD |
| | | | ||
| | | | ||
- | | x | + | | x |
| | | | ||
|- | |- |
Versie op 19 mei 2010 08:18
Naam | Firma |
Consultatie/ advisering | Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus |
Kees Brinkman | Viiv | x | x | x | |
BMS | x | ||||
MSD | x | x | |||
Gilead | x | x | x | ||
Roche | x | ||||
Abbott | x | x | |||
Jansen-Tibotec | x | x | x | ||
Mariska Tuut | Geen | ||||
Suzanne Geerlings | MSD | x | x | ||
GSK | x | ||||
BMS | x | x | |||
Gilead | x | x | |||
Abbott | x | x | |||
Jansen Cilag (Tibotec) | x | ||||
Pfizer | x | ||||
Jet Gisolf | |||||
Gerrit Schreij | Viiv Healthcare | x | x | ||
Gilead | x | ||||
Tibotec | x | ||||
Roche | x | ||||
MSD | x | ||||